Integrated Biopharma Inc 8-K Filing

FAQ

Key Financial Figures

• $0.002 — f the Company's common stock, par value $0.002 per share, were entitled to vote as of

Filing Documents

• inbp20251201_8k.htm (8-K) — 52KB
• 0001437749-25-036573.txt ( ) — 170KB
• inbp-20251201.xsd (EX-101.SCH) — 3KB
• inbp-20251201_def.xml (EX-101.DEF) — 10KB
• inbp-20251201_lab.xml (EX-101.LAB) — 14KB
• inbp-20251201_pre.xml (EX-101.PRE) — 10KB
• inbp20251201_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On December 1, 2025, Integrated BioPharma, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 31,059,610 shares of the Company's common stock, par value $0.002 per share, were entitled to vote as of the close of business on October 17, 2025, the record date for the Annual Meeting. The holders of 22,651,488 shares of common stock, representing a quorum, were present in person or represented by proxy at the Annual Meeting, at which the stockholders were asked to vote on four proposals. The proposals are described in detail in the Company's definitive proxy materials which were filed with the Securities and Exchange Commission and first made available to stockholders on or about October 28, 2025 (the "Definitive Proxy Statement"). Set forth below are the matters acted upon by the Company's shareholders at the Annual Meeting, and the final voting results of each such proposal. Proposal No. 1 – To elect the Class III director for a three-year term to serve until the 2028 Annual Meeting of Stockholders The Company's stockholders voted for the election of the Class III director, Mr. Eric Friedman, to serve until the 2028 Annual Meeting of Stockholders (subject to earlier removal, death or resignation) and until his successor is elected and qualified. The final voting results were as follows: Broker For Withheld Non-Votes Eric Friedman 20,662,516 183,398 1,805,574 Proposal No. 2 – Non-binding, Advisory Vote on Frequency of Vote on Executive Compensation The Company's shareholders voted, by a non-binding advisory vote, for a three-year frequency of vote on executive compensation. The final non-binding advisory voting results were as follows: 1 Year 2 Years 3 Years Abstain 445,580 800 20,395,034 4,500 Proposal No. 3 – Non-binding advisory vote on Executive Compensation The Company's stockholders voted, by a non-binding advisory vot

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 5.07 shall be deemed to be furnished, and not filed: 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1- EXHIBIT INDEX Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTEGRATED BIOPHARMA, INC. Date: December 1, 2025 By: /s/ Dina L Masi Dina L Masi Chief Financial Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR